As a safe and minimal-invasive modality, thermal therapy has become an effective treatment in cancer treatment. Other than killing the tumor cells or destroying the tumor entirely, the thermal modality results in profound molecular, cellular and biological effects on both the targeted tissue, surrounding environments, and even the whole body, which has triggered the combination of the thermal therapy with other traditional therapies as chemotherapy and radiation therapy or new therapies like immunotherapy, gene therapy, etc. The combined treatments have shown encouraging therapeutic effects both in research and clinic. In this review, we have summarized the outcomes of the existing synergistic therapies, the underlying mechanisms that lead to these improvements, and the latest research in the past five years. Limitations and future directions of synergistic thermal therapy are also discussed.
Objective: Tumor Treating Fields (TTFields), a non-invasive cancer therapy employing low-intensity alternating electric fields to inhibit cancer cell division, has been used to treat glioblastoma. While clinically established for glioblastoma, the biological contribution of the intrinsic mild hyperthermia (iMH) remains not fully elucidated, limiting mechanistic clarity and treatment optimization. Approach: This study presents a precision in vitro platform designed to decouple the electrical and thermal components of TTFields (230 kHz, 2 V/cm). Based on numerical simulations, the platform utilizes a defined monitoring area to ensure field uniformity and an active thermodynamic compensation protocol to isolate electric and thermal modalities. Main results: Results indicated that the electric field primarily inhibited cell proliferation (32.0% reduction) and migration, whereas the iMH was the primary mediator of cytotoxicity and apoptosis. Notably, the combined electrothermal treatment exhibited a synergistic anti-tumor effect exceeding the additive effects of individual modalities. Significance: These findings suggest that the iMH component of TTFields functions as a therapeutic sensitizer rather than a side effect, offering a basis for optimizing future GBM treatment strategies.
3 March 2026 in IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology
To design and validate a real-time precision control system for radiofrequency ablation (RFA) that counteracts power instability from dynamic tissue impedance, ensuring accurate and predictable energy delivery.An integrated system was developed with high-precision RF signal acquisition and two novel algorithms: an impedance-adaptive voltage correction to eliminate measurement errors, and a Taylor series-based feedforward control for rapid ($< $ 50ms) power adjustments. Performance was validated using an electrosurgical analyzer (20-500 $\Omega$ load range) and through ex vivo ablation experiments on porcine liver, chicken breast, and pork tissues.The system achieved high measurement accuracy, with voltage/current errors $< $ 3% and impedance/power errors $< $ 4%. The impedance-adaptive algorithm reduced voltage control error by 90% under non-nominal loads. Ex vivo ablations demonstrated excellent lesion repeatability, with ablation zone area discrepancies under 1.24%. The integrated hardware-software solution provides a validated method to enhance the predictability and consistency of RFA. Ensuring consistent RFA energy delivery, this technology creates predictable ablation zones, enhancing efficacy and safety by reducing tumor recurrence and minimizing damage to surrounding healthy tissue.